octobre 23, 2023
Arexvy was approved by Health Canada in Aug. for people aged 60 and older and costs an estimated $270 per dose in N.B. The Coalition for Seniors and Nursing Home Residents' Rights calls the decision to not publicly fund the RSV vaccine unacceptable. At the very least, the organization argues, the province should cover the cost for seniors with respiratory problems. Last fall and winter, N.B. recorded more than 1,500 RSV cases - the highest number in at least a decade. The province could revisit its decision not to cover the cost of the vaccine for seniors.
Lire l'article